Rose McNulty

The FDA's decision represents a landmark approval of a tumor-derived cellular therapy in a solid tumor cancer.

Real-time continuous glucose monitoring (CGM) demonstrated benefits associated with time in range, hypoglycemia, and hyperglycemia in patients with type 1 diabetes (T1D).

Patients using a predictive alarm saw a reduction of more than 40% in time spent below range in hypoglycemia and more than 60% in time spent in severe hypoglycemia.

A new study found that participants reported improved glycemic control and improved quality of life with smartwatch-integrated, do-it-yourself continuous glucose monitoring.